Jaime Xinos - Achieve Life Executive Commercial
| ACHV Stock | USD 3.07 0.22 7.72% |
Executive
Jaime Xinos is Executive Commercial of Achieve Life Sciences
| Phone | 604-210-2217 |
| Web | https://www.achievelifesciences.com |
Jaime Xinos Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jaime Xinos against Achieve Life stock is an integral part of due diligence when investing in Achieve Life. Jaime Xinos insider activity provides valuable insight into whether Achieve Life is net buyers or sellers over its current business cycle. Note, Achieve Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Achieve Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jaime Xinos over a week ago Acquisition by Jaime Xinos of 20000 shares of Achieve Life at 3.32 subject to Rule 16b-3 | ||
Jaime Xinos over three months ago Insider Trading |
Achieve Life Management Efficiency
The company has return on total asset (ROA) of (0.5409) % which means that it has lost $0.5409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8604) %, meaning that it created substantial loss on money invested by shareholders. Achieve Life's management efficiency ratios could be used to measure how well Achieve Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MRCP MD | Coherus BioSciences | 55 | |
| Marcia Belvin | CytomX Therapeutics | N/A | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| JD Esq | Apellis Pharmaceuticals | 52 | |
| Vladimir Vexler | Coherus BioSciences | 66 | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Jami Taylor | Coherus BioSciences | N/A | |
| Jodi Sievers | Coherus BioSciences | N/A | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| Ann Hargraves | Tscan Therapeutics | N/A | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Zoran JD | Tscan Therapeutics | 55 | |
| Ben JD | Immix Biopharma | N/A | |
| David MD | Iteos Therapeutics | N/A | |
| Adam JD | Day One Biopharmaceuticals | 58 | |
| Scott Saywell | Coherus BioSciences | N/A | |
| JD Esq | Acumen Pharmaceuticals | 54 | |
| Michael Alonso | Bolt Biotherapeutics | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Steven CPA | NextCure | 62 | |
| Stacy Rollinger | NextCure | N/A | |
Management Performance
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 |
Achieve Life Sciences Leadership Team
Elected by the shareholders, the Achieve Life's board of directors comprises two types of representatives: Achieve Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Achieve. The board's role is to monitor Achieve Life's management team and ensure that shareholders' interests are well served. Achieve Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Achieve Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cindy MD, Chief President | ||
| Jaime Xinos, Executive Commercial | ||
| Mark CPA, Chief Officer | ||
| Jerry Wan, Principal Officer | ||
| Anthony Clarke, President Chief Scientific Officer, Director | ||
| Richard Stewart, Chairman of the Board, CEO | ||
| John MBA, CEO Director | ||
| Thomas MBA, Executive Chairman | ||
| Craig Donnelly, Executive CMC | ||
| Mark Rubinstein, Head Affairs |
Achieve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Achieve Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 64.95 M | ||||
| Shares Outstanding | 34.39 M | ||||
| Shares Owned By Insiders | 9.72 % | ||||
| Shares Owned By Institutions | 59.62 % | ||||
| Number Of Shares Shorted | 3.81 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Book | 3.12 X | ||||
| EBITDA | (26.73 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Achieve Stock Analysis
When running Achieve Life's price analysis, check to measure Achieve Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Achieve Life is operating at the current time. Most of Achieve Life's value examination focuses on studying past and present price action to predict the probability of Achieve Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Achieve Life's price. Additionally, you may evaluate how the addition of Achieve Life to your portfolios can decrease your overall portfolio volatility.